Apart from beneficial effects demonstrated in different experimental models of cancer [49], it has been increasingly shown that pharmacological targeting of the up-regulated p300/CBP activity with C646 inhibitor represents a promising way to intervene in the progression of metabolic and cardiovascular disorders. Here, EP300 is linked to cancer.